NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
31 March 2025
| Name: | IMRICOR MEDICAL SYSTEMS, INC. (IMR) |
| ISIN: | AU0000054942 |
| Date of Listing: | 30 August 2019 |
Stock Exchange Status: (updated daily)
This entity is currently suspended from quotation on the Australian Securities Exchange and its securities cannot be traded on-market.Legal Status: (updated monthly)
ACN: 633 106 019
Registration Date: 26 April 2019
Capital Gains Tax (CGT) Status: (updated at least quarterly)
The securities in this entity may be suspended from quotation for reasons unrelated to its financial health or we have made the assessment that the securities still have value. If you are seeking to crystallise a capital loss on your securities, you should firstly consider whether your company is the subject of either a takeover or that you will be able to sell your securities on-market for value if the entity regains quotation. Entities in this category are reviewed monthly and it is possible that our assessment may change. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Imricor Medical Systems Inc will be lifted immediately following the release by IMR of an announcement regarding a capital raise. | 20/03/2025 |
The company releases its Equity Raising Presentation. | 20/03/2025 |
The company has completed a successful capital raise of A$70 million, raising $44.1 million through a strongly-supported placement to sophisticated investors. The proceeds will be used to accelerate Imricor's growth strategy, including expanding commercial operations and supporting regulatory efforts. | 20/03/2025 |
The securities of Imricor Medical Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising. | 19/03/2025 |
The suspension of trading in the securities of Imricor Medical Systems, Inc. will be lifted immediately following the release by IMR of an announcement regarding a proposed capital raising. | 05/02/2024 |
The Company has received firm commitments for its institutional placement placement to US investors and the institutional component of its 1 for 7.5 pro-rata accelerated non-renounceable entitlement offer of new CHESS Depositary Interests. The Institutional Placement, US Placement and Institutional Entitlement Offer will raise approximately A$8.0 million in total at an issue price of A$0.45 per CDI and share. The offer was well supported by existing shareholders as well as attracting new institutional shareholders to the register. | 05/02/2024 |
The company releases a Capital Raising Presentation. | 02/02/2024 |
The company releases a cleansing notice for the capital raising earlier announced. | 02/02/2024 |
The company releases a notice of proposed issue of securities. | 02/02/2024 |
The Company is undertaking an institutional placement, a placement to US investors and an entitlement offer to raise up to ~A$15.0 million. | 02/02/2024 |
The securities of Imricor Medical Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising. | 02/02/2024 |
The suspension of trading in the securities of Imricor Medical Systems, Inc. will be lifted immediately following the release by IMR of an announcement regarding a proposed capital raising. | 24/10/2023 |
The Company has completed a placement to raise A$4.28 million. Investors outside the US purchased a total of 7,126,000 CDIs at A$0.50 per CDI. These investors also received 10-year warrants to purchase a total of 1,781,500 additional CDIs at A$0.95 per CDI. The Company has drawn A$145,822 as a second tranche from the A$30 million Security Subscription Facility with GEM Global Yield SCS. The draw was a partial draw, cancelled before completion due to the Placement. The Company is issuing 309,600 CDIs to GGY at an issue price of approximately A$0.471 per CDI. The funds received are expected to be applied in a similar manner to those raised under the Placement. The issue price represents 90% of the average closing bid price of the Company's CDIs over the 15 consecutive trading days that followed the submission of the draw down notice to GGY, as adjusted in accordance with the terms of the SSF. | 24/10/2023 |
The securities of Imricor Medical Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising. | 23/10/2023 |
listed entity carried for record purposes only | 30/08/2019 |
The suspension of trading in the securities of Imricor Medical Systems Inc will be lifted immediately following the release by IMR of an announcement regarding a capital raise. | 20/03/2025 |
The company releases its Equity Raising Presentation. | 20/03/2025 |
The company has completed a successful capital raise of A$70 million, raising $44.1 million through a strongly-supported placement to sophisticated investors. The proceeds will be used to accelerate Imricor's growth strategy, including expanding commercial operations and supporting regulatory efforts. | 20/03/2025 |
The securities of Imricor Medical Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising. | 19/03/2025 |
The suspension of trading in the securities of Imricor Medical Systems, Inc. will be lifted immediately following the release by IMR of an announcement regarding a proposed capital raising. | 05/02/2024 |
The Company has received firm commitments for its institutional placement placement to US investors and the institutional component of its 1 for 7.5 pro-rata accelerated non-renounceable entitlement offer of new CHESS Depositary Interests. The Institutional Placement, US Placement and Institutional Entitlement Offer will raise approximately A$8.0 million in total at an issue price of A$0.45 per CDI and share. The offer was well supported by existing shareholders as well as attracting new institutional shareholders to the register. | 05/02/2024 |
The company releases a Capital Raising Presentation. | 02/02/2024 |
The company releases a cleansing notice for the capital raising earlier announced. | 02/02/2024 |
The company releases a notice of proposed issue of securities. | 02/02/2024 |
The Company is undertaking an institutional placement, a placement to US investors and an entitlement offer to raise up to ~A$15.0 million. | 02/02/2024 |
The securities of Imricor Medical Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising. | 02/02/2024 |
The suspension of trading in the securities of Imricor Medical Systems, Inc. will be lifted immediately following the release by IMR of an announcement regarding a proposed capital raising. | 24/10/2023 |
The Company has completed a placement to raise A$4.28 million. Investors outside the US purchased a total of 7,126,000 CDIs at A$0.50 per CDI. These investors also received 10-year warrants to purchase a total of 1,781,500 additional CDIs at A$0.95 per CDI. The Company has drawn A$145,822 as a second tranche from the A$30 million Security Subscription Facility with GEM Global Yield SCS. The draw was a partial draw, cancelled before completion due to the Placement. The Company is issuing 309,600 CDIs to GGY at an issue price of approximately A$0.471 per CDI. The funds received are expected to be applied in a similar manner to those raised under the Placement. The issue price represents 90% of the average closing bid price of the Company's CDIs over the 15 consecutive trading days that followed the submission of the draw down notice to GGY, as adjusted in accordance with the terms of the SSF. | 24/10/2023 |
The securities of Imricor Medical Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising. | 23/10/2023 |
listed entity carried for record purposes only | 30/08/2019 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 07/05/2024 | Peter McGregor | 100,000 | $0.484 | $48,368 |
| 16/03/2023 | Mark Tibbles | 505,000 | $0.340 | $171,700 |
| 10/03/2023 | Mark Tibbles | 574,451 | $0.340 | $195,313 |
| 02/03/2023 | Steve Wedan | 97,540 | $0.320 | $31,213 |
| 14/11/2022 | Steve Wedan | 23,000 | $0.371 | $8,540 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Steve Wedan | Chairman, CEO | 25/05/2006 |
| Gregg Stenzel | COO | 30/12/2020 |
| Jonathon Gut | CFO | 01/07/2022 |
| Peter McGregor | Non Exec Director | 19/05/2019 |
| Anita Messal | Non Exec Director | 01/03/2021 |
| Mark Tibbles | Non Exec Director | 05/09/2014 |
| Kobe Li | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Lori Milbrandt | CFO | 30/06/2022 | |
| Doris Engibous | Non Exec Director | 13/04/2019 | 01/03/2021 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
